Ezetimibe

Pharmacologic Category

Antilipemic Agent, 2-Azetidinone

Dosing: Adult

Note: Use may be considered in patients who do not meet cholesterol treatment goals with dietary modification and maximally-tolerated statin therapy (AHA/ACC [Grundy 2018]).

Homozygous familial hypercholesterolemia: Oral: 10 mg once daily.

Homozygous sitosterolemia: Oral: 10 mg once daily.

Primary hyperlipidemia: Oral: 10 mg once daily.

Secondary prevention of atherosclerotic cardiovascular events after acute coronary syndrome (off-label use): Oral: 10 mg once daily (Cannon 2015).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

No dosage adjustment necessary.

Dosing: Hepatic Impairment: Adult

Mild impairment (Child-Pugh class A): No dosage adjustment necessary.

Moderate to severe impairment (Child-Pugh class B or C): Use of ezetimibe not recommended.

Dosing: Pediatric

Hyperlipidemia:

Children 5 to 9 years: Limited data available: Oral: 10 mg once daily; dosing based on two studies of monotherapy; a prospective trial (n=17 including six patients ≤9 years) and a retrospective review (n=36, age range: 8 to 17 years) showed significant decreases in total cholesterol and LDL-C; patients were followed up to a mean of 13.6 months, no untoward effects were noted (Clauss 2009; Yeste 2009)

Children ≥10 years and Adolescents: Oral: 10 mg once daily in combination with simvastatin. Has also been shown in small pediatric trials to decrease TC and LDL-C when used as monotherapy as adjunct to dietary changes (Clauss 2009; Yeste 2009)

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Renal Impairment: Pediatric

Children ≥10 years and Adolescents: No dosage adjustments are recommended.

Dosing: Hepatic Impairment: Pediatric

Children ≥10 years and Adolescents:

Mild hepatic impairment (Child-Pugh score 5-6): No dosage adjustments are recommended.

Moderate to severe impairment (Child-Pugh score 7-15): Use is not recommended.

Use: Labeled Indications

Homozygous familial hypercholesterolemia: In combination with a high-intensity statin (eg, atorvastatin) for the reduction of elevated total cholesterol (total-C) and low-density lipoprotein cholesterol (LDL-C) levels in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable.

Homozygous sitosterolemia: As adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.

Primary hyperlipidemia: As adjunctive therapy to diet and an HMG-CoA reductase inhibitor or as monotherapy if an HMG-CoA reductase inhibitor is not tolerated for the reduction of total-C, LDL-C, apolipoprotein B, and nonhigh-density lipoprotein cholesterol in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed hyperlipidemia.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

​Secondary prevention of atherosclerotic cardiovascular events after acute coronary syndromeLevel of Evidence [A]

Data from a multicenter, randomized, double-blind, placebo-controlled trial of patients with a recent acute coronary syndrome (ACS) support the addition of ezetimibe to statin therapy to reduce subsequent cardiovascular death, major coronary event (nonfatal myocardial infarction, unstable angina requiring hospitalization, or coronary revascularization within 30 days), or nonfatal stroke. Patients were eligible for this trial if ACS events occurred within 10 days and LDL cholesterol was ≥50 mg/dL) Ref.

Based on the 2018 AHA/ACC guideline on the management of blood cholesterol, the addition of ezetimibe to maximally tolerated statin therapy is effective and recommended for secondary prevention of atherosclerotic cardiovascular disease.

Level of Evidence Definitions

​Level of Evidence Scale

Comparative Efficacy

• EZETIMIBE

Clinical Practice Guidelines

Diabetes Mellitus:

AACE/ACE, “Consensus Statement on the Comprehensive Type 2 Diabetes Management Algorithm- 2019 Executive Summary,” January 2019

ADA, “Standards of Medical Care in Diabetes - 2020,” January 2020

Dyslipidemia:

AACE/ACE, “Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease,” April 2017

ACC, “2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk,” October 2017

ACC/AHA, “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults,” November 2013

AHA/ACC, “Guideline on the management of blood cholesterol,” November 2018

Canadian Cardiovascular Society, “2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult, 2012”

NLA, “National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia” Part 1: April 2015; Part 2: December 2015

The Kidney Disease: Improving Global Outcomes (KDIGO), “Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline,” December 2013

Administration: Oral

May be administered without regard to meals. May be taken at the same time as a statin or fenofibrate. Administer ≥2 hours before or ≥4 hours after bile acid sequestrants.

Administration: Pediatric

Oral: May be taken without regard to meals or time of day; may be administered with an HMG-CoA reductase inhibitor (eg, atorvastatin, simvastatin) or fenofibrate. Administer ≥2 hours before or ≥4 hours after bile acid sequestrants.

Dietary Considerations

Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 6 weeks and the diet should be continued during drug therapy.

Storage/Stability

Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect from moisture.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to lower cholesterol.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Joint pain

• Diarrhea

• Loss of strength and energy

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Muscle pain

• Muscle weakness

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Medication Safety Issues

​Sound-alike/look-alike issues:

Contraindications

Hypersensitivity to ezetimibe or any component of the formulation; concomitant use with an HMG-CoA reductase inhibitor (statin) in patients with active hepatic disease or unexplained persistent elevations in serum transaminases; pregnancy and breastfeeding (when used concomitantly with a statin)

Warnings/Precautions

Concerns related to adverse effects:

• Elevated hepatic transaminases: A higher incidence of elevated transaminases (≥3 x ULN) has been observed with concomitant use of ezetimibe and statins compared to statin monotherapy; transaminase changes were generally not associated with symptoms or cholestasis and returned to baseline with or without discontinuation of therapy. Consider discontinuation of ezetimibe and/or the statin for persistently elevated transaminases (ALT or AST ≥3 x ULN).

• Myopathy: Myopathy, including rhabdomyolysis, has been reported (rarely) with ezetimibe monotherapy; risk may be increased with concomitant use of a statin or fibrate. Discontinue ezetimibe and statin or fibrate immediately if myopathy is suspected or confirmed (symptomatic patient with CPK >10 x ULN).

Disease-related concerns:

• Hepatic impairment: Systemic exposure is increased in hepatic impairment. Use with caution in patients with mild hepatic impairment (Child-Pugh class A); use is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh classes B and C).

• Renal impairment: Use with caution in patients with severe renal impairment (CrCl ≤30 mL/minute/1.73 m2); systemic exposure is increased ~1.5-fold. If using concurrent simvastatin in patients with moderate to severe renal impairment (CrCl <60 mL/minute/1.73m2), the manufacturer of ezetimibe recommends that simvastatin doses exceeding 20 mg be used with caution and close monitoring for adverse events (eg, myopathy).

Other warnings/precautions:

• Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

The definition of and, therefore, when to treat hyperlipidemia in the elderly is a controversial issue. According to the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, there are no supporting data for the routine use of nonstatin drugs in combination with a statin to further reduce atherosclerotic cardiovascular disease (ASCVD) events. Evidence for nonstatins in statin-intolerant patients is also lacking (Stone 2013). It is the authors' belief that pharmacologic treatment be reserved for those who are unable to obtain a desirable plasma cholesterol concentration by diet alone and for whom the benefits of treatment are believed to outweigh the potential adverse effects, drug interactions, and cost of treatment.

Pregnancy Risk Factor

C

Pregnancy Considerations

Adverse events were observed in some animal reproduction studies. Use is contraindicated in pregnant women who require combination therapy with an HMG-CoA reductase inhibitor. If treatment for familial hypercholesterolemia is needed during pregnancy, other agents are preferred (Wiegman 2015).

Breast-Feeding Considerations

It is not known if ezetimibe is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Use is contraindicated in breastfeeding women who require combination therapy with an HMG-CoA reductase inhibitor.

Briggs' Drugs in Pregnancy & Lactation

• Ezetimibe

Adverse Reactions

1% to 10%:

Central nervous system: Fatigue (2%)

Gastrointestinal: Diarrhea (4%)

Hepatic: Increased serum transaminases (with HMG-CoA reductase inhibitors; ≥3 x ULN: 1%)

Infection: Influenza (2%)

Neuromuscular & skeletal: Arthralgia (3%), limb pain (3%)

Respiratory: Upper respiratory tract infection (4%), sinusitis (3%)

<1%, postmarketing, and/or case reports: Abdominal pain, anaphylaxis, angioedema, autoimmune hepatitis (Stolk 2006), cholecystitis, cholelithiasis, cholestatic hepatitis (Stolk 2006), depression, dizziness, erythema multiforme, headache, hepatitis, hypersensitivity reaction, increased creatine phosphokinase, myalgia, myopathy, nausea, pancreatitis, paresthesia, rhabdomyolysis, skin rash, thrombocytopenia, urticaria

* See Cautions in AHFS Essentials for additional information.

Metabolism/Transport Effects

Substrate of OATP1B1/1B3 (SLCO1B1/1B3)

Drug Interactions Open Interactions

Bile Acid Sequestrants: May decrease the absorption of Ezetimibe. Management: Administer ezetimibe at least 2 hours before or 4 hours after any bile acid sequestrant. Risk D: Consider therapy modification

CycloSPORINE (Systemic): Ezetimibe may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Ezetimibe. Risk C: Monitor therapy

Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates. Risk C: Monitor therapy

Fenofibrate and Derivatives: May enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. Fenofibrate and Derivatives may increase the serum concentration of Ezetimibe. Risk C: Monitor therapy

Fibric Acid Derivatives: May enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. Fibric Acid Derivatives may increase the serum concentration of Ezetimibe. Exceptions: Fenofibrate and Derivatives. Risk X: Avoid combination

Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates. Risk C: Monitor therapy

Tolvaptan: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates. Management: Avoid concomitant use of OATP1B1/1B3 substrates in patients receiving the Jynarque brand of tolvaptant. Concentrations and effects of the OATP1B1/1B3 substrate would be expected to increase with combined use. Risk D: Consider therapy modification

Monitoring Parameters

ACC/AHA blood cholesterol guideline recommendations (ACC/AHA [Grundy 2018]; ACC/AHA [Stone 2013]):

Lipid panel (total cholesterol, HDL, LDL, triglycerides): Lipid profile (fasting or nonfasting) before initiating treatment. Fasting lipid profile should be rechecked 4 to 12 weeks after starting therapy and every 3 to 12 months thereafter (AHA/ACC [Grundy 2018]).

Hepatic transaminase levels: Baseline LFTs (reasonable); when used in combination with statin therapy, monitor LFTs when clinically indicated; discontinue use of ezetimibe if ALT elevations >3 times upper limit of normal persist. When used in combination with fenofibrate, monitor LFTs and signs and symptoms of cholelithiasis.

Reference Range

Treatment goals: May vary depending on clinical condition, different clinical practice guidelines, and expert opinion. Refer to clinical practice guidelines for specific treatment goals.

Advanced Practitioners Physical Assessment/Monitoring

Use caution in presence of hepatic impairment. If used as monotherapy, dose adjustment is unnecessary in renal impairment. Assess lipid profile at beginning of and at regular intervals during therapy. Teach patient to report signs of hepatic or muscle reactions.

Nursing Physical Assessment/Monitoring

Assess lipid profile at beginning of and at regular intervals during therapy. Teach patient to report signs of hepatic or muscle reactions. Consider dietary assessment and plan for teaching.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Zetia: 10 mg

Generic: 10 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Ezetrol: 10 mg

Generic: 10 mg

Anatomic Therapeutic Chemical (ATC) Classification

• C10AX09

Generic Available (US)

Yes

Pricing: US

Tablets (Ezetimibe Oral)

10 mg (per each): $2.62 - $13.21

Tablets (Zetia Oral)

10 mg (per each): $13.80

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Inhibits absorption of cholesterol at the brush border of the small intestine via the sterol transporter, Niemann-Pick C1-Like1 (NPC1L1). This leads to a decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and an increased clearance of cholesterol from the blood; decreases total C, LDL-cholesterol (LDL-C), ApoB, and triglycerides (TG) while increasing HDL-cholesterol (HDL-C).

Pharmacodynamics/Kinetics

Note: Pharmacokinetic data in children and adolescents ≥10 years of age are reported to be similar to that in adult patients.

Onset of action: Within 1 week; Maximum effect: 2-4 weeks

Protein binding: >90% to plasma proteins

Metabolism: Undergoes glucuronide conjugation in the small intestine and liver; forms metabolite (active); may undergo enterohepatic recycling

Bioavailability: Variable

Hepatic impairment: Moderate hepatic impairment (Child-Pugh score 7-9): AUC increased 3-4 times; Severe hepatic impairment (Child-Pugh 10-15): AUC increased 5-6 times

Renal impairment: Severe renal dysfunction (CrCl <30 mL/minute/1.73 m2): AUC increased 1.5 times

Half-life elimination: 22 hours (ezetimibe and metabolite)

Time to peak, plasma: 4-12 hours (ezetimibe); 1-2 hours (active metabolite); Effects: ~2 weeks

Excretion: Feces (78%, 69% as ezetimibe); urine (11%, 9% as metabolite)

Pharmacodynamics/Kinetics: Additional Considerations

Geriatric: Plasma concentrations are approximately 2-fold higher.

Gender: Plasma concentrations for total ezetimibe were slightly higher (less than 20%) in women than in men.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

FDA Approval Date

October 25, 2002

References

American Diabetes Association (ADA). 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018a;41(suppl 1): S86-S104. doi: 10.2337/dc18-S009.[PubMed 29222380]10.2337/dc18-S009

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397.[PubMed 26039521]

Clauss S, Wall K, Kavey RW, et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154:869-872.

Daniels SR, Greer FR, and Committee on Nutrition, "Lipid Screening and Cardiovascular Health in Childhood," Pediatrics, 2008, 122(1):198-208.[PubMed 18596007]

Ezetrol (ezetimibe) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; October 2017.

Gagne C, Gaudet D, Bruckert E, et al, “Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia,” Circulation, 2002, 105(21):2469-75.[PubMed 12034651 ]

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol [published online November 10, 2018]. Circulation. 2018.[PubMed 30586774]

Gustavson LE, Schweitzer SM, Burt DA, et al, “Evaluation of the Potential for Pharmacokinetic Interaction Between Fenofibrate and Ezetimibe: A Phase I, Open-Label, Multiple-Dose, Three-Period Crossover Study in Healthy Subjects,” Clin Ther, 2006, 28 (3):373-87.[PubMed 16750452]

Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2 [published correction appears in J Clin Lipidol. 2016;10(1):211]. J Clin Lipidol. 2015;9(6)(suppl):S1-S122.e1.[PubMed 26699442]

Jacobson TA, Marman A, McKenney JM, et al, “Safety Considerations With Gastrointestinally Active Lipid-Lowering Drugs,” Am J Cardiol, 2007, 99(6A):47C-55C.[PubMed 17368279]

Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.[PubMed 28437620]10.4158/EP171764.APPGL

Mauro VF and Tuckerman CE, “Ezetimibe for Management of Hypercholesterolemia,” Ann Pharmacother, 2003, 37(6):839-48.[PubMed 12773075]

McCrindle BW, Urbina EM, Dennison BA, et al, "Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing," Circulation, 2007, 115(14):1948-67.[PubMed 17377073]

National Heart, Lung, and Blood Institute. Expert panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. Available at http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf

Peto R, Emberson J, Landray M, et al, “Analysis of Cancer Data From Three Ezetimibe Trials,” N Engl J Med, 2008, 359(13):1357-66. Available at http://content.nejm.org/cgi/content/full/NEJMsa0806603[PubMed 18765432]

Rossebo AB, Pederson TR, Boman K, et al, “Intensive Lipid Lowering With Simvastatin and Ezetimibe in Aortic Stenosis,” N Engl J Med, 2008, 359(13):1343-56. Available at http://content.nejm.org/cgi/content/full/NEJMoa0804602[PubMed 18765433 ]

Stolk MF, Becx MC, Kuypers KC, et al, “Severe Hepatic Side Effects of Ezetimibe,” Clin Gastroenterol Hepatol, 2006, 4(7):908-11.[PubMed 16797241]

Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].Circulation. 2013.

“Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),” May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.

“Three New Drugs for Hyperlipidemia,” Med Lett Drugs Ther, 2003, 45(1151):17-9.[PubMed 12612501]

von Bergmann K, Salen G, Lutjohann D, et al, “Ezetimibe Effectively Reduces Serum Plant Sterols in Patients With Sitosterolemia (abstract).” 73rd European Atherosclerosis Society Congress, 2002. Available at http://www.kenes.com/73eas/program/abstracts/405.doc

Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014;160(3):182. doi: 10.7326/M13-2453.[PubMed 24323134]

Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-2437. doi: 10.1093/eurheartj/ehv157.[PubMed 26009596]

Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metabl. 2009;22(6):487-492.[PubMed 19694195]

Zetia (ezetimibe) [prescribing information]. Whitehouse Station, NJ: Merck/Schering-Plough; August 2013.

Brand Names: International

Absorcol (ES); Centex (PY); Cholinor (BD); Ezemibe (LK); Ezentia (TH); Ezeta (BD); Ezetib (IN); Ezetrol (AE, AR, AT, AU, BD, BE, BG, BH, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IS, JO, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TW, VE, VN); Ezgal (BE); Ezitab (BD); Ezitoget (VN); Ibet (PY); Ledipsa (PH); Maxetibe (PY); Mibe (LK); Zemil (LB); Zemitra (PK); Zetavim (UY); Zetex (SA); Zetia (BR, JP, PE); Zient (CR, DO, GT, HN, MX, NI, PA, SG, SV); Zytovyrin (VN)

Last Updated 10/17/20